Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject must give signed informed consent before any study-related activities.~* The partner, if applicable, must give signed informed consent before administration of Somatuline Autogel.~* The subject must be able to understand the protocol requirements.~* The subject must have a clinical diagnosis of acromegaly due to pituitary tumor.~* The subject must be treated with a long-acting somatostatin analogue with or without a dopamine agonist and have been on the current medical regimen for at least 3 months prior to screening and have IGF-1 levels no higher than 10% above the upper limit of the normal range for age and gender at the screening visit or be somatostatin analogue naïve (if the subject is treated with a dopamine agonist he/she must have been on the current dose for at least 3 months prior to screening).~* Subjects who are treated with a dopamine agonist have to stay on their current dose for the duration of the study.~* Switch subjects must have had their last pre-study routine clinical treatment with Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment).~* The subject must be able to store the study medication in a refrigerator in his/her own or his/her partner's home.~* The subject must be ≥18 years of age.~* Female subjects of childbearing potential must use adequate contraception.~* Female subjects of childbearing potential who are taking oral contraceptives must agree to stay on their current contraceptive dose for the duration of the study.~* The partner, if applicable, must be ≥18 years of age.~Exclusion Criteria:~* The subject has had pituitary surgery (adenomectomy) within 3 months prior to screening.~* The subject has received pituitary radiotherapy within 3 years prior to screening.~* The subject has received a GH receptor antagonist within 6 months prior to screening.~* The subject is currently on a higher dose of Sandostatin LAR than 30mg q28d~* The subject is pregnant or breastfeeding.~* The subject has clinically significant renal or hepatic abnormalities.~* The subject has a symptomatic, untreated biliary lithiasis.~* The subject has uncontrolled diabetes or thyroid disease.~* The subject has a known hypersensitivity to any of the test materials or related compounds.~* The subject is unable or unwilling to comply with the protocol.~* The subject has received any investigational drug within 30 days prior to screening.~* The subject has participated in a medical device study within 30 days prior to screening.~* The subject has previously participated in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Somatuline Autogel (lanreotide acetate) (Type: EXPERIMENTAL): Somatuline Autogel (lanreotide acetate) Injection

Based on this trial design, predict the completion outcome and termination type (if applicable).